BACKGROUND: Although the use of highly active antiretroviral therapy in the treatment of HIV infection has led to considerable improvement in morbidity and mortality, unless patients are adherent to their drug regimen (i.e., at least 90 to 95% of doses taken), viral replication may ensue and drug-resistant strains of the virus may emerge. METHODS: The authors studied the extent to which neuropsychological compromise and medication regimen complexity are predictive of poor adherence in a convenience sample of 137 HIV-infected adults. Medication adherence was tracked through the use of electronic monitoring technology (MEMS caps). RESULTS: Two-way analysis of variance revealed that neurocognitive compromise as well as complex medication regimens were associated with significantly lower adherence rates. Cognitively compromised participants on more complex regimens had the greatest difficulty with adherence. Deficits in executive function, memory, and attention were associated with poor adherence. Logistic regression analysis demonstrated that neuropsychological compromise was associated with a 2.3 times greater risk of adherence failure. Older age (>50 years) was also found to be associated with significantly better adherence. CONCLUSIONS: HIV-infected adults with significant neurocognitive compromise are at risk for poor medication adherence, particularly if they have been prescribed a complex dosing regimen. As such, simpler dosing schedules for more cognitively impaired patients might improve adherence.
BACKGROUND: Although the use of highly active antiretroviral therapy in the treatment of HIV infection has led to considerable improvement in morbidity and mortality, unless patients are adherent to their drug regimen (i.e., at least 90 to 95% of doses taken), viral replication may ensue and drug-resistant strains of the virus may emerge. METHODS: The authors studied the extent to which neuropsychological compromise and medication regimen complexity are predictive of poor adherence in a convenience sample of 137 HIV-infected adults. Medication adherence was tracked through the use of electronic monitoring technology (MEMS caps). RESULTS: Two-way analysis of variance revealed that neurocognitive compromise as well as complex medication regimens were associated with significantly lower adherence rates. Cognitively compromised participants on more complex regimens had the greatest difficulty with adherence. Deficits in executive function, memory, and attention were associated with poor adherence. Logistic regression analysis demonstrated that neuropsychological compromise was associated with a 2.3 times greater risk of adherence failure. Older age (>50 years) was also found to be associated with significantly better adherence. CONCLUSIONS:HIV-infected adults with significant neurocognitive compromise are at risk for poor medication adherence, particularly if they have been prescribed a complex dosing regimen. As such, simpler dosing schedules for more cognitively impairedpatients might improve adherence.
Authors: R H Haubrich; S J Little; J S Currier; D N Forthal; C A Kemper; G N Beall; D Johnson; M P Dubé; J Y Hwang; J A McCutchan Journal: AIDS Date: 1999-06-18 Impact factor: 4.177
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: V Tozzi; P Balestra; S Galgani; P Narciso; F Ferri; G Sebastiani; C D'Amato; C Affricano; F Pigorini; F M Pau; A De Felici; A Benedetto Journal: AIDS Date: 1999-10-01 Impact factor: 4.177
Authors: David J Moore; Miguel Arce; Suzanne Moseley; J Allen McCutchan; Jennifer Marquie-Beck; Donald R Franklin; Florin Vaida; Cristian L Achim; Justin McArthur; Susan Morgello; David M Simpson; Benjamin B Gelman; Ann C Collier; Christina M Marra; David B Clifford; Robert K Heaton; Igor Grant Journal: J Neuropsychiatry Clin Neurosci Date: 2011 Impact factor: 2.198
Authors: Saurabh Gupta; Steven Paul Woods; Erica Weber; Matthew S Dawson; Igor Grant Journal: J Clin Exp Neuropsychol Date: 2010-04-27 Impact factor: 2.475
Authors: Mark L Ettenhofer; Jessica Foley; Nina Behdin; Andrew J Levine; Steven A Castellon; Charles H Hinkin Journal: Arch Clin Neuropsychol Date: 2010-08-26 Impact factor: 2.813
Authors: Doyle E Patton; Steven Paul Woods; Donald Franklin; Jordan E Cattie; Robert K Heaton; Ann C Collier; Christina Marra; David Clifford; Benjamin Gelman; Justin McArthur; Susan Morgello; David Simpson; J Allen McCutchan; Igor Grant Journal: AIDS Behav Date: 2012-11
Authors: Amelia J Poquette; David J Moore; Ben Gouaux; Erin E Morgan; Igor Grant; Steven Paul Woods Journal: J Int Neuropsychol Soc Date: 2012-10-25 Impact factor: 2.892